Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Python turns 32. Explore 32 practical Python one-liners that show why readability, simplicity, and power still define the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results